EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Dose reductions of liposomal irinotecan and oxaliplatin did not compromise overall survival in patients with metastatic PDAC on NALIRIFOX.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in the ASCEND trial.

Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.